Incidence and risk factors for cardiovascular disease in African Americans with diabetes: The Atherosclerosis Risk in Communities (ARIC) study

Journal of the National Medical Association

Volumn 94, Issue 12, 2002, Pages 1025-1035

  Adeniyi, Ayokanmi ^b   Folsom, Aaron R ^a   Brancati, Frederick L ^b   Desvarieux, Moise ^b   Pankow, James S ^b   Taylor, Herman ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

Cardiovascular disease; Coronary heart disease; Diabetes stroke

Indexed keywords

AFRICAN AMERICAN; ARTICLE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; ETHNOLOGY; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; RISK FACTOR; STATISTICS; UNITED STATES;

AFRICAN AMERICANS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; UNITED STATES;

EID: 0036984744     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134-1146.
2. Krolewski AS, Czyzyk A, Janeczko D, Kopczynski J. Mortality from cardiovascular diseases among diabetics. Diabetologia. 1977;13:345-350.
3. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care. 1979;2:120-126.
4. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health. 1991;81: 1158-1162.
5. Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. 1997;20:935-942.
6. Gillum RF. Risk factors for stroke in blacks: A critical review. Am J Epidemiol. 1999;150:1266-1274.
7. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
8. th, 1992, Bethesda, MD. Arterioscler Thromb. 1993;13:459-464.
9. Standl E, Balletshofer B, Dahl B, et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia. 1996;39:1540-1545.
10. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med. 1996;28:371-380.
11. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary disease incidence among persons with diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med. 2000;133: 81-91.
12. Folsom AR, Ma J, Eckfeldt JH, Nieto FJ, Metcalf PA, Barnes RW. Low serum albumin: Association with diabetes mellitus and other cardiovascular risk factors but not with prevalent cardiovascular disease or carotid artery intima-media thickness. Ann Epidemiol. 1995;5:186-191.
13. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J. 1990;120:672-676.
14. Missov RM, Stolk RP, van der Bom JG, et al. Plasma fibrinogen in NIDDM: the Rotterdam study. Diabetes Care. 1996; 19:157-159.
15. Fuller JH, Stevens LK, Wang SL. Risk factors for cardiovascular mortality and morbidity: The WHO multinational study of vascular disease in diabetes. Diabetolagia. 2001;44(Suppl 2): S54-S64.
16. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129:687-702.
17. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr. 1982;36:936-942.
18. Gindler EM, Heth DA. Colorimetric determination with bound "Calmagite" of magnesium in human blood serum [Abstract]. Clin Chem. 1971;17:662.
19. Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromocresol green. Clin Chim Acta. 1971;31:87-96.
20. Eckfeldt JH, Chambless LE, Shen YL. Short-term, within-person variability in clinical chemistry test results. Experience from the Atherosclerosis Risk in Communities Study. Arch Pathol Lab Med. 1994;118:496-500.
21. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem. 1983;29:1075-1080.
22. Nagele U, Hagele EO, Sauer G, et al. Reagent for the enzymatic determination of serum total trigylcerides with improved lipolytic efficiency. J Clin Chem Clin Biochem. 1984;22:165-174.
23. 2+ precipitation [abstract]. Clin Chem. 1982;28: 1574.
24. Patsch W, Brown SA, Morrisett JD, Gotto AM Jr, Patsch JR. A dual-precipitation method evaluated for measurement of cholesterol in high-density lipoprotein subfractions HDL2 and HDL3 in human plasma. Clin Chem. 1989;35:265-270.
25. Schonfeld G, Pfleger B. The structure of human high-density lipoprotein and the levels of apolipoproteins A-I in plasma as determined by radioimmunoassay. J Clin Invest. 1974; 54:236-246.
26. Maciejko JJ, Mao SJ. Radioimmunoassay of alipoprotein A-I. Application of a non-ionic detergent (Tween-20) and solid-phase staphylococcus. Clin Chem. 1982;28:199-204.
27. Schonfeld G, Lees RS, George PK, Pfleger B. Assay of total plasma apolipoprotein B concentration in human subjects. J Clin Invest. 1974;53:1458-1467.
28. Gaubatz JW, Ghanem KI, Guevara J Jr, Nava ML, Patsch W, Morrisett JD. Polymorphic forms of human apolipoprotein(a): inheritance and relationship of their molecular weights to plasma levels of lipoprotein (a). J Lipids Res. 1990;31:603-613.
29. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1997;96:1102-1108.
30. Anonymous. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1197.
31. Prineas RJ, Crow RS, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings: Standard and Procedures for Measurement and Classification. Littleton, Mass: John Wright; 1982.
32. White AD, Folsom AR, Chambless LE, et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study: methods and initial two years' experience. J Clin Epidemiol. 1996;49:223-233.
33. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: nine-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30:736-743.
34. Rautaharju PM, Warren JW, Jain U, Wolf HK, Nielsen CL. Cardiac infarction injury score: an electrocardiograghic coding scheme for ischemic heart disease. Circulation. 1981;64:249-256.
35. Jones DW, Chambless LE, Folsom AR, et al. Risk factors for coronary heart disease in African-Americans: The Atherosclerosis Risk in Communities study, 1987-1997. Arch Intern Med. 2002; in press.
36. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study. BMJ. 1998; 316:823-828.
37. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993:16;434-444.
38. Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost. 1993;70:380-385.
39. Morigi M, Angioletti S, Imberti B, et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest. 1998;101:1905-1915.
40. Ernst E, Hammerschmidt DE, Bagge U, Matrai A, Dormandy JA. Leukocytes and the risk of ischemic diseases. JAMA. 1987;257:2318-2324.
41. Kinlay S, Selwyn AP, Libby P, Ganz P. Inflammation, the endothelium, and the acute coronary syndromes. J Cardiovasc Pharmacol. 1998;32[suppl 3]:S62-S66.
42. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992;340:319-323.
43. Mattock MB, Barnes DJ, Viberti G, et al. Microalbuminuria and coronary heart disease in NIDDM: an incident study. Diabetes. 1998;47:1786-1792.
44. Turner RC, Holman RR, Cull CA, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
45. Malmberg K. Prospective randomised study of intensive insulin treatment on longterm survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) study group. BMJ. 1997;314:1512-1515.
46. Harris MI. Noninsulin-dependent diabetes mellitus in black and white Americans. Diabetes Metab Rev. 1990;6:71-90.
47. DeStefano F, Newman J. Comparison of coronary heart disease mortality risk between black and white people with diabetes. Ethnicity Dis. 1993;3:145-151.
48. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. In: National Diabetes Data Group, ed. Diabetes in America. Bethesda, MD: US Dept. of Health and Human Services, Public Health Service, National Institutes of Health: 1995:233-257.
49. Tull ES, Roseman JM. Diabetes in African Americans. In: National Diabetes Data Group, ed. Diabetes in America. Bethesda, MD: US Dept of Health and Human Services, Public Health Service, National Institutes of Health;1995:613-630.
50. Stehouwer CD, Gall MA, Hougaard P, Jakobs C, Parving HH. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int. 1999;55:308-314.
51. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult Treatment Panel III). JAMA. 2001;285:2486-2497.
52. Colwell JA. Aspirin therapy in diabetes. Diabetes Care. 1997;20:1767-1771.